Keyword: Bristol-Myers Squibb
PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment.
Doctors in Paris discovered that when they treated an HIV-infected lung cancer patient with Opdivo, reservoirs of the virus shrunk.
Innate Pharma said it can’t see an obvious way to bring its cancer antibody lirilumab forward in development after it flunked a second clinical trial.
Pfizer creates COO role, Bayer replaces consumer health chief, Turnstone poaches Bristol-Myers executive as new R&D head and more.
Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D.
The heavily pretreated bladder cancer data suggest the cocktail can hold its own against a combination of rival drugs from Incyte and Merck.
Scientists from the University of Chicago and Mount Sinai are exploring different methods of improving checkpoint-inhibiting cancer drugs.
We kick off a new long form series assessing the life science industry from its leaders with ex-Teva chief Jeremy Levin.
PathAI, which teamed up with Philips on cancer diagnostics in March, has bagged $11 million in series A financing.
The goal is to use Dicerna’s GalXC technology to silence previously inaccessible drug targets, thereby restoring liver function.